Pfizer's blockbuster drug Viagra (sildenafil citrate), hitherto approved for use in treatment of erectile dysfunction, may soon acquire a new identity as a "life saving drug" in treating pulmonary arterial hypertension in children.
The venue of the battle by Swiss multinational Novartis AG against the rejection of its patent application for blockbuster cancer drug Gleevac will now shift to the Patent Appellate Board's office.
Australia has joined the UK, USA and Canada in warning its citizens against using unapproved traditional medicines from India and China.
Hetero is the only Indian partner of multinational drug major Roche Scientific for the manufacture and supply of the latter's patented drug, Tamilflu in developing countries.
Merck is all set to introduce three of its money-spinning drugs - Cosopt, Invanz and Pneuvax in India.
Pharmaceutical companies which increase prices of their medicines beyond 10 per cent in a year will face regulatory action.
The resultant price increase was the cause of a surprise upward variation in the "drug and medicines" segment of the weekly wholesale price index of the ministry of commerce and Industry last week, it is learnt.
Sipika Singh switched careers from being a senior consultant with Ernst and Young to a regional marketing role in the pharma major, Novartis in Singapore.
With the bidding for the generics business of Merck set to begin from Monday, domestic pharmaceutical companies in the fray, Ranbaxy Laboratories and Dr Reddy's Laboratories, are unlikely to go for an all-out bidding war.
The decision has come in the wake of allegations of plagiarism against the Mashelkar panel report.
"The product technology is coming from DNDi. Cipla will manufacture and make the product available in southeast Asia and other parts of the world at affordable pre-agreed prices," Amar Lulla, joint managing director, Cipla, said.
Feedback Ventures, an infrastructure consulting company, Arcelor-Mittal, and Reliance Retail are among the 25-30 companies that went to the Indian Institute of Management, Ahmedabad (IIM-A) this time.
The international health organisations, protesting against Swiss pharmaceutical major Novartis AG's legal challenge to provisions of the Indian Patent Act
Even as the domestic pharmaceutical industry is exploring new markets in Latin America and the Commonwealth of Independent States, exports to countries in Africa are declining.
Having cut eight deals last year, the $1.3 billion pharma major Ranbaxy probably has the sharpest negotiating skills in the business.
Despite an expected 150 per cent increase in central spending on higher education in 2007-08
Ministry to amend Act to bring all oral, skin and hair care products under its purview.
Shortage of trained professionals in the financial markets has prompted the need for specialised courses in stock markets and commodity training.
Ranbaxy Laboratories, the biggest member of the Indian Pharmaceutical Alliance, has come out in the open against the alliance's stand on patent issues.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances